This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this book Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Copland, J. A. Articles by Urban, R. J. Search for Related Content PubMed PubMed Citation Articles by Copland, J. A. Articles by Urban, R. J.

The Use of DNA Microarrays to Assess Clinical Samples: The Transition from Bedside to Bench to Bedside

John A. Copland^*, Peter J. Davies, Gregory L. Shipley, Christopher G. Wood, Bruce A. Luxon^|| and Randall J. Urban^*

^* Endocrinology Division, Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555
Department of Pharmacology, University of Texas-Houston Medical School, Houston, Texas 77030
Urology Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030
^|| Human Biological Chemistry & Genetics Departments, University of Texas Medical Branch, Galveston, Texas 77555

The advent of gene array technology brings the ability to classify disease states to the molecular level by examining changes in all mRNAs expressed in cells or tissues. Comparing changes in gene expression patterns between normal and diseased cells and/or tissues has elucidated unique subsets of genes identifiable to a specific disease. Already, new subclassifications of specific cancers have been discovered, belying that genomic profiling can uniquely distinguish a specific disease state and tissue of origin. This technology bestows the ability to examine global changes occurring in a cell or tissue(s), thereby allowing the elucidation of alterations in dysregulated biological, biochemical, and molecular events leading to disease states such as diabetes, hypertension, infertility, obesity, osteoporosis, and atherosclerosis. Furthermore, genomic profiling will lead to new molecular targets for the development of drug therapeutics. Futuristically, one could envision personalized patient therapies based upon identification of specific aberrant signaling pathways that can be targeted for drug therapy.

This article has been cited by other articles:

				M. L. Gumz, H. Zou, P. A. Kreinest, A. C. Childs, L. S. Belmonte, S. N. LeGrand, K. J. Wu, B. A. Luxon, M. Sinha, A. S. Parker, et al. Secreted Frizzled-Related Protein 1 Loss Contributes to Tumor Phenotype of Clear Cell Renal Cell Carcinoma Clin. Cancer Res., August 15, 2007; 13(16): 4740 - 4749. [Abstract] [Full Text] [PDF]

				K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring Molecular Diagnosis of Cutaneous Diseases Arch Dermatol, February 1, 2005; 141(2): 225 - 241. [Abstract] [Full Text] [PDF]